Converting suspension-type human primary hepatocytes to be plateable-type for use as an in vitro pharmacokinetics model
Drug Metabolism and Pharmacokinetics · 2025
DOI: 10.1016/j.dmpk.2024.101044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2025. Verfasst von Raghda Shahin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan; Department of Clinical Pharmacy, …. Hauptthemen laut MEDLINE: Hepatocytes, Models, Biological, Pharmacokinetics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Preclinical animal models cannot precisely predict medication failures in clinical trials. Human primary hepatocytes (HPHs) are the gold standard for in vitro culture systems that recapitulate in vivo human liver characteristics. Consequently, demand for HPHs is rising despite their high cost, batch-to-batch variability, and inadequate supply. Existing commercial HPHs are plateable (pHPHs) and suspension (sHPHs) using same isolation and cryopreservation technique. The sHPHs cannot be cultured on the plate surface or cannot efficiently relocalize efflux transporters. They can also have a life of maximum of 2-4 h. Therefore, they are unsuitable for assays requiring well-organized efflux transporters or long-term studies, such as enzyme induction or metabolic assays for low-turnover drugs. We aim to develop a novel pharmacokinetic model of converted sHPHs to be attached like pHPHs. We successfully cultured sHPHs as 2D sandwich-cultured sHPHs for use as a promising, reproducible, and affordable in vitro model for efflux trans-porter assays, cytochrome P450 induction, and metabolic studies. The sHPHs successfully attached, converted to be plateable, similar morphology, and mRNA expression as pHPHs, as well as detectable metabolic activity and extended lifespan. Overall, this study is the first to culture functional 2D sandwich sHPHs as a novel in vitro pharmacokinetic model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan; Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan; Laboratory of Biological Chemistry, School of Pharmaceutical Sciences, Wakayama Medical University, Wak…
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan. Electronic address: tiwao@phar.nagoya-cu.ac.jp.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Shahin, R., Sakai, Y., Shirai, K., Hashita, T., Matsunaga, T., & Iwao, T. (2025). Converting suspension-type human primary hepatocytes to be plateable-type for use as an in vitro pharmacokinetics model. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2024.101044
Vancouver
Shahin R, Sakai Y, Shirai K, Hashita T, Matsunaga T, Iwao T. Converting suspension-type human primary hepatocytes to be plateable-type for use as an in vitro pharmacokinetics model. Drug Metabolism and Pharmacokinetics. 2025. doi:10.1016/j.dmpk.2024.101044
BibTeX
@article{Shahin2025,
author = {Shahin, Raghda and Sakai, Yoko and Shirai, Kotaro and Hashita, Tadahiro and Matsunaga, Tamihide and Iwao, Takahiro},
title = {Converting suspension-type human primary hepatocytes to be plateable-type for use as an in vitro pharmacokinetics model},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2025},
doi = {10.1016/j.dmpk.2024.101044}
}
EUVIMED